Biologics Contract Manufacturing Market
Biologics Contract Manufacturing Market Study by Monoclonal Antibodies, Recombinant Proteins, Insulin, Vaccines, Interferons, and Growth Factors from 2024 to 2034
Analysis of Biologics Contract Manufacturing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Biologics Contract Manufacturing Market Outlook (2024 to 2034)
The global biologics contract manufacturing market size is estimated at US$ 21.19 billion in 2024, as per a new Fact.MR industry report. Worldwide demand for biologics contract manufacturing is predicted to rise at a noteworthy 9.4% CAGR and reach a market value of US$ 51.81 billion by the end of 2034.
Increasing cases of chronic diseases along with a shift to personalized medicines is predicted to contribute to the rising demand for biologic drugs, which is subsequently generating the need for contract manufacturing services. Constant technological advancements taking place in biotechnology, especially in fields such as cell culture technologies, protein expression systems, and genetic engineering, are predicted to increase the complexity of biological drug manufacturing and expand their scope of application, thus stimulating the need for specialized manufacturing expertise.
Majority of biopharmaceutical companies generally opt for contract manufacturing to minimize capital investment in infrastructure. Furthermore, they are placing a strong emphasis on expanding their manufacturing facilities to increase their production capacity. Stringent regulations governing biopharmaceutical manufacturing are predicted to increase these companies’ dependency on contract manufacturing organizations (CMOs) with expertise in regulatory compliance, thus ensuring adherence to safety protocols and quality standards.
- Demand for biologics contract manufacturing services in North America is predicted to accelerate at 9.5% CAGR and reach a value of US$ 2.58 billion by 2034-end.
- The commercial segment is predicted to account for 73.8% of biologics contract manufacturing market share by 2034.
- Revenue from biologics contract manufacturing services in oncology is projected to increase at a CAGR of 8.3% and reach US$ 12.30 billion by 2034-end.
Strategic collaborations between biologics contract manufacturing and biopharma companies are projected to contribute to market expansion while combining capabilities, resources, and expertise. Biologics contract manufacturing services are projected to be in high demand due to the increased need for prompt vaccine development and improved manufacturing capabilities. This is primarily due to their cost-effectiveness when compared to original biologics.
| Report Attributes | Details |
|---|---|
| Biologics Contract Manufacturing Market Size (2024E) | US$ 21.19 Billion |
| Forecasted Market Value (2034F) | US$ 51.81 Billion |
| Global Market Growth Rate (2024 to 2034) | 9.4% CAGR |
| Canada Market Growth Rate (2024 to 2034F) | 8.2% CAGR |
| East Asia Market Share (2034F) | 5.3% |
| Monoclonal Antibodies Segment Growth Rate (2024 to 2034) | 8.3% CAGR |
| Oncology Segment Market Share (2034F) | 23.8% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Responsible for High Demand for Biologics Contract Manufacturing?
“Focus on Outsourcing R&D Activities to Minimize Operation Costs”
The biopharmaceutical CMO sector is expected to grow and undergo consolidation as companies pursue strategies to offer integrated solutions to their customers. Ongoing scientific advancements in biopharmaceuticals are predicted to create opportunities for players with high potential.
For instance :
- AGC Biologics, in July 2020, completed the acquisition of Molecular Medicine S.p.A. to add to its capabilities in gene therapy and plasmid production services. The company’s revenue stream is expected to be impacted by the presence of companies with advanced biologic and biosimilar manufacturing facilities.
Focus on minimizing operation costs through the commercialization of biopharmaceuticals and outsourcing of R&D activities for product innovations is predicted to enhance operational effectiveness. In addition, outsourcing at the later stages of clinical development with the assistance of appointment and identification of a strategic partner is predicted to improve the effectiveness of the value chain.
The emerging model of CDMO business, disruptive drug development, transformation taking place in the pharmaceutical ecosystem, and expansion of biopharmaceutical manufacturing are predicted to drive growth opportunities in the market over the next decade.
Which Factors Can Adversely Impact Market Growth Going Forward?
“Changing Regulatory Framework Resulting in Increased Cost of Products”
Regulatory policies along with stringent inspection regimes are predicted to cause issues in the security of the supply chain across several emerging countries and are projected to have adverse effects on the prices of end products. Start-ups trying to enter this space face financial challenges due to the abovementioned factors, therefore making their entry an expensive affair.
“Dearth of Skilled Manpower Hampering Global Market Growth”
The contribution of skilled professionals is vital for economic development in emerging regions. Reports from various companies indicate a notable gap in the workforce between the number of available skilled professionals and the increasing demand in specific industries. Poor planning, shortage of skilled individuals, and inadequate funding are forecasted to hamper market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Initiatives are Start-ups Taking to Secure Their Market Position?
“Focus on Process Improvements and Technological Innovations”
Continuous innovations taking place in manufacturing technologies, including improved analytics, process automation, and single-use systems, are forecasted to lead to enhanced yield and productivity, which is further contributing to the biologics contract manufacturing market growth. Furthermore, the cost-efficiency of these newly developed systems is also predicted to help new entrants get a competitive edge.
Country-wise Insights
Demand for biologics contract manufacturing services in North America is projected to advance at a CAGR of 9.5% and reach a value of US$ 2.58 billion by the end of 2034. The presence of several key players and their involvement in the production of high-quality and cost-efficient solutions is forecasted to contribute to the expansion of the biologics contract manufacturing market size.
Why is Demand for Biologics Contract Manufacturing Services High in the United States?
“Well-Established Biological Pipelines and Heavy Investments in Healthcare”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 931.8 Million |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 2.34 Billion |
The United States is forecasted to account for 90.6% share of the market in North America by 2034. The nation boasts well-established biological pipelines and increased capital investments, which is fueling demand for biologics contract manufacturing. In addition, the establishment of many research institutions and the presence of manufacturers with specialized methodologies are contributing to market expansion.
Why are Biologics Contract Manufacturing Service Providers Eyeing China?
“Growing Collaborations between Industry Players and Local Manufacturing Organizations”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 763.3 Million |
| Growth Rate (2024 to 2034) | 10.1% CAGR |
| Projected Value (2034F) | US$ 2 Billion |
China is predicted to hold 72.4% share of the East Asia market by 2034. Several biopharma and pharma companies are focusing on capitalizing on their growth by looking for opportunities to collaborate with various local organizations to establish themselves.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Fact.MR, a market research and competitive intelligence provider, in its newly published study, asserts that the demand for monoclonal antibodies is predicted to increase further owing to their increased use in treatments for chronic Hepatitis B (HBV) infection, cancer, autoimmune diseases, and infectious diseases.
Why Do Monoclonal Antibodies Account for Higher Demand?
“Rising Traction for Antibody Therapeutics in Biopharmaceuticals”
| Attribute | Monoclonal Antibodies |
|---|---|
| Segment Value (2024E) | US$ 8.9 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 19.8 Billion |
Monoclonal antibodies are predicted to account for 38.2% share of the global market by 2034. The favorable safety profile and excellent specificity of monoclonal antibodies contribute to their increased use in biologics for the manufacturing of biopharmaceuticals. Biologics contract manufacturing market trends are expected to be driven by the increasing demand for various antibody-based treatments.
Which Platform is Projected to Gain Prominence among End Users?
“Enhanced Efficiency and Speed of Mammalian-Based Processes”
| Attribute | Mammalian |
|---|---|
| Segment Value (2024E) | US$ 15.55 Billion |
| Growth Rate (2024 to 2034) | 9.7% CAGR |
| Projected Value (2034F) | US$ 39.27 Billion |
The mammalian category is projected to hold 75.8% share of global market revenue by 2034. With reduced completion time and enhanced efficiency in mammalian-based processes, the platform is expected to gain more traction. Mammalian cell cultures, such as CHO cells, are projected to be preferred for biopharmaceutical manufacturing over other similar platforms.
What’s Contributing to Rising Demand for Biologics Contract Manufacturing in Oncology?
“Increasing Research Activities in Clinical Settings to Discover Novel Therapeutic Options”
| Attribute | Oncology |
|---|---|
| Segment Value (2024E) | US$ 5.56 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 12.3 Billion |
The oncology segment is predicted to account for 23.8% share of the global market by 2034. The rising prevalence of oncologic conditions such as cancer is expected to drive demand for biologics contract manufacturing in this domain. Moreover, the entry of multiple manufacturers with innovative product lines and the increasing research activities in clinical settings to discover novel therapeutic options are poised to further fuel market expansion.
Which End-use Segment is Projected to Hold a Leading Market Share?
“Commercial Segment Accounts for Leading Market Share Due to Focus on Facility Expansion”
| Attribute | Commercial Sector |
|---|---|
| Segment Value (2024E) | US$ 15.26 Billion |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 38.24 Billion |
The commercial segment is forecasted to account for 73.8% share of global market revenue by 2034. Growing need for biologic medications and scaling up of contract manufacturing facilities is projected to contribute to revenue streams in the commercial segment in the coming 10 years.
Competitive Landscape
Prominent companies in the market focus on the distribution network across the globe to generate revenue streams. They are also investing in the management of supply chain systems, new developments, product quality, etc.
For instance :
- Abzena Limited, in November 2021, established a collaboration with BiVictriX Therapeutics Plc. for the manufacturing of BiVictriX’s ADC (antibody-drug conjugates).
Key players in the biologics contract manufacturing market are Lonza Group AG, BioXcellence, Samsung Biologics, AbbVie CM, Fujifilm Diosynth Biotechnologies, AGC Biologics, Patheon N.V., Ajinomoto Bio-Pharma, Emergent BioSolutions Inc., Avid Bioservices, Inc., Rentschler Biotechnologies GmbH, KBI Biopharma, Merck KGaA, Novasep, Therapure Biopharma Inc., Abzena Plc., and ProBioGen AG.
Segmentation of Biologics Contract Manufacturing Market Research
-
By Product:
- Monoclonal Antibodies
- Recombinant Proteins
- Insulin
- Vaccines
- Interferons
- Growth Factors
- Others
-
By Platform:
- Mammalian
- Microbial
-
By Therapeutic Area:
- Oncology
- Metabolic Diseases
- Autoimmune Diseases
- Ophthalmology
- Infectious Diseases
- Cardiovascular Diseases
- Neurology
- Respiratory Disorders
- Others
-
By Application:
- Commercial
- Clinical
-
By Region:
- North America
- Europe
- East Asia
- Latin America
- Middle East & Africa
- South Asia & Oceania
- FAQs -
How big is the size of the biologics contract manufacturing market?
The global biologics contract manufacturing market is pegged at US$ 21.19 billion in 2024.
What is the demand projection for biologics contract manufacturing for 2034?
Demand for biologics contract manufacturing services is predicted to reach a market value of US$ 51.81 billion by 2024.
What is the projected growth rate for the global market?
The global market is forecasted to expand at 9.4% CAGR from 2024 to 2034.
What is the demand outlook for mammalian-based biologics contract manufacturing services?
Demand for mammalian-based biologics contract manufacturing is projected to increase at 9.7% CAGR and reach a value of US$ 39.27 billion by 2034-end.
At what rate is the United States market foreseen to expand?
The market in the United States is predicted to advance at 9.6% CAGR from 2024 to 2034.
What is the demand projection for biologics contract manufacturing facilities in oncology?
Demand for biologics contract manufacturing in oncology is projected to reach a market value of US$ 12.3 billion by the end of 2034.
Biologics Contract Manufacturing Market
*Mail attachment includes 219 figures & 80 tables